Phreesia, Inc. (NYSE:PHR) General Counsel Sells $123,336.50 in Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison C. Hoffman sold 4,585 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $26.90, for a total value of $123,336.50. Following the completion of the sale, the general counsel now directly owns 154,552 shares of the company’s stock, valued at $4,157,448.80. This represents a 2.88 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Phreesia Stock Up 1.6 %

Shares of PHR stock opened at $27.24 on Friday. Phreesia, Inc. has a one year low of $17.07 and a one year high of $29.16. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The stock has a fifty day moving average price of $23.54 and a 200 day moving average price of $22.81. The stock has a market cap of $1.58 billion, a P/E ratio of -18.53 and a beta of 0.94.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million for the quarter, compared to analyst estimates of $106.33 million. During the same period in the previous year, the business earned ($0.58) EPS. The firm’s revenue was up 16.6% on a year-over-year basis. Analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Hedge Funds Weigh In On Phreesia

Several hedge funds and other institutional investors have recently modified their holdings of the stock. International Assets Investment Management LLC raised its stake in Phreesia by 2,179.7% during the third quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock worth $33,000 after acquiring an additional 1,395 shares in the last quarter. Lombard Odier Asset Management USA Corp acquired a new stake in shares of Phreesia during the 2nd quarter worth about $202,000. Point72 DIFC Ltd bought a new position in Phreesia during the 2nd quarter valued at about $209,000. XTX Topco Ltd bought a new stake in Phreesia during the third quarter worth about $247,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Phreesia during the second quarter worth approximately $301,000. Institutional investors own 92.10% of the company’s stock.

Wall Street Analyst Weigh In

PHR has been the subject of a number of recent analyst reports. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research report on Tuesday, December 10th. KeyCorp raised their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Wednesday, January 8th. Royal Bank of Canada raised shares of Phreesia from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $24.00 to $32.00 in a research report on Wednesday, January 8th. Truist Financial raised their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Citigroup boosted their price objective on Phreesia from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $31.00.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.